Dyne Therapeutics, Inc. (DYN) Financial Statements
Free cash flow over the same period: -$499.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DYNDyne Therapeutics, Inc.Follow DYN — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 0.05 | 0.12 | 0.14 | 0.21 | 0.28 | 0.40 | 0.45 | |
| Operating income | -0.06 | -0.15 | -0.17 | -0.24 | -0.34 | -0.47 | -0.54 | |
| Pre-tax income | -0.06 | -0.15 | -0.17 | -0.24 | -0.32 | -0.45 | -0.52 | |
| Income tax | — | — | — | — | — | 0.00 | — | |
| Net income | -0.06 | -0.15 | -0.17 | -0.24 | -0.32 | -0.45 | -0.52 | |
| Diluted EPS ($) | -4.13 | -2.93 | -3.23 | -3.95 | -3.37 | -3.47 | -3.30 |
USD billions · SEC XBRL
Dyne Therapeutics, Inc. — questions
- What is Dyne Therapeutics, Inc.'s net income?
- -$519.4M over the twelve months to 2026-06-30.
- What is Dyne Therapeutics, Inc.'s free cash flow?
- -$499.2M over the twelve months to 2026-06-30.
- What are Dyne Therapeutics, Inc.'s diluted earnings per share?
- $-3.30 over the twelve months to 2026-06-30.
Every figure on this page comes from Dyne Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.